PanGen Biotech

PanGen Biotech Equity

The The Equity of PanGen Biotech (222110.KQ) as of Oct 20, 2026 is 29.92 B KRW. In the previous year, The Equity was 24.91 B KRW — a change of 20.14% (higher).

Equity

29.92 BKRW

YoY

20.14%

Last updated:

In 2025, PanGen Biotech's equity was 29.92 B KRW, a 20.14% increase from the 24.91 B KRW equity in the previous year.

The PanGen Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
26.94 B KRW
Jan 1, 2019
18.43 B KRW
Jan 1, 2020
14.21 B KRW
Jan 1, 2021
21.10 B KRW
Jan 1, 2022
17.22 B KRW
Jan 1, 2023
12.57 B KRW
Jan 1, 2024
24.91 B KRW
Jan 1, 2025
29.92 B KRW
The PanGen Biotech Equity history
YEAREquityYoY
29.92 BKRW+20.14%
24.91 BKRW+98.22%
12.57 BKRW-27.02%
17.22 BKRW-18.38%
21.10 BKRW+48.46%
14.21 BKRW-22.88%
18.43 BKRW-31.60%
26.94 BKRW-13.95%
31.31 BKRW-11.32%
35.31 BKRW+438.14%
6.56 BKRW-20.11%
8.21 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

PanGen Biotech Stock analysis

What does PanGen Biotech do? PanGen Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing PanGen Biotech's Equity

PanGen Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding PanGen Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating PanGen Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

PanGen Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in PanGen Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about PanGen Biotech stock

The Equity of PanGen Biotech is 29.92 B KRW in 2025.

The Equity of PanGen Biotech changed from 24.91 B KRW to 29.92 B KRW, representing a 20.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity PanGen Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's PanGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — PanGen Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — PanGen Biotech